Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Me too. Treats her special..just listen.
Yes, if it is how they make their living.....
Iiiverson, just listen to her on the call. Harvey treats her very nicely. Listen to his responses to her, plz.
Rachel McMinn will probably raise Ariad to a buy from a neutral after ASCO, and after Ariad reaches $19.. Neutral from $4 to $19, then a buy.. Yeah, that is about it..
Vid, she has mostly been a research assistant. That was my point. Listen to her on the calls. I think she will do well, but certainly not seasoned.
A little detail on the analyst covering Ariad at Summer Street (I hear her on the Ariad calls all the time). I dare say she is young, inexperienced, and bold in her target adjustment from $16 to $21. Who knows, a career enhancing call? Stay tuned..
Ling Wang, CFA
Senior Biotechnology Analyst
Ling Wang, CFA, was previously a senior vice president and senior biotechnology analyst at Brean Murray, Carret & Co. Prior to her work at Brean Murray, Ms. Wang was a research associate covering biotechnology stocks at Rodman & Renshaw from 2006 to 2008. From 2004 to 2006 she was a research assistant in the life science group at Manning & Napier Advisors, Inc., an investment firm with approximately $16 billion in assets under management. Ms. Wang earned her undergraduate degree in biology from Beijing University. She also holds a master's degree in molecular pharmacology from Albert Einstein College of Medicine and an MBA degree in finance from Yale University.
Sure.....
Anybody a little surprised by this strength?
Interestingly, they also hired back a person who use to be with the firm as a new Chief Science Officer, with an incredible background. See link in firt article as it can not be posted.
Rida in phII NSCLC at ASCO??
http://www.biopharmcatalyst.com/asco2012/
Ariad is now interviewing/hiring the front line sales team. With all the chatter, they should be able to hire some of the best. Notice their lead tag line:
http://www.linkedin.com/jobs?viewJob=&jobId=3017559&srchIndex=2
While it does appear to be frothy here on the Ariad message board, her is a stock (PCYC) that also climbed the wall of worry and never looked back. I believe this is the model for Ariad with the sequence of events of June 4th for Pona, and early October for Ap26113
http://finance.yahoo.com/q/bc?s=PCYC+Basic+Chart&t=5y
Rachel McMinn may be paid $350K (are you sure? that is not very much), but she has consistantly failed to understand and provide top shelf research on Ariad.
- She doesn't follow Ariad very closely? LOL - do you expect MLCO to pay her $350,000/year and a bonus just so she can write a research report for you to misunderstand?
Her report on ariad is flawed, she missed some import points.
- She doesn't cover Ariad "at all". LOL - interesting. So, MLCO is violating FINRA and SEC rules by publishing her name on the reports when shes not "covering Ariad at all"? Maybe you should tell Merrill, I'm sure they would love to know what you found in your in depth research on Rachel. This was done by an assistant not her, no doubt. You do know that it is in complete SEC compliance for analysts to use assistants, don't you?
- She had a "hold" on ARIA from $4 to $17? Wow, this is really interesting. Please show the entire board here where Rachel and MLCO were even covering ARIA at $4.00, let alone, $10.00? Doesn't matter..she has ALWAYS HAD A HOLD.
- Claims 18% dilution. It's called a "model". It's what analysts do. Doesn't matter what they do. As I said, her model is flawed, she doesn't understand the warrents, doesn't fully understand the company.
I expect that for now on she now will come out of the woods, and actually do a little research on her own.. She covers way too many stocks
Nope, not options, but a secondary offering in 2013. I think McMinn is dead wrong on the 18% dilution. That's way out of line if Ariad is in the 20's in 2013, as it should be with an approved Pona.. As I said, she really doesn't follow Ariad very closely. In fact, she doesn't cover Ariad at all.. seems like it is a staffer that covers Ariad for her, as she made three mistakes, imho, didn't know about warrents, claims 18% dilution, and has had a hold from $4 to $17.
Glass, it was the CFO and not Harvey that made that statement.
Well,accounting wise, the CFO stated that the warrents have all been accounted for, and will no longer effect the financial statements.
Rachel McMinn named top biotech analyst in WSJ’s- doesn't mean that much. Name the top biotech analyst for each year, over the last 5 years.. See what I mean...
Sorry Dew, you and Rachel McMinn missed the huge run up in Ariad.
Rachel McMinn named top biotech analyst in WSJ’s.. doesn't mean much..
Name me the top biotech analyst in WSJ's survey, each year, over the last 5 years.. See what I mean...
IIIverson, you are killing me...lol....
Cowen has some coverage in the WSJ, but I just have a hard copy at another location.
http://online.wsj.com/article/SB10001424052702303815404577335521018234082.html
First upgrade, Jefferies, PT $18
http://zolmax.com/jefferies-group-sets-ariad-pharmaceutical-price-target-at-18-00-aria/298118/
iandy, it was a great call, and Harvy's attitude is infectious. No matter what anyone says, he is truly a great leader. Look at all the key scientist there... 17 to 20 years with the 'Harv...
The other good news is the overhang of the warrents is now done..
iAndy, the fourth cohort of the phase II will allow other cancers to enter the trial (i.e., other solid tumors), and will also represents the opportunity to explore the effectiveness with the blood-brain barrier (this was the Merrill analyst's question). Tim indicated they could explore this then, but didn't commit..
Searching for upgrades this morning... Come on, I know you can do it..
From the call today, what is stunning to me is that the analysts basically asked Harvey in ten different ways if AP26113 worked. If they only spent a little time here, or on unmentioned patient blogs, they would know the answer.. Yes, it does.. These guys are working the old fashion way.....
I think there was only one firm that included AP26113 in their financial model, so I would expect the other firms to start to add a little value for it. If not now, then surely in the fall..
iandy, why did you remove your Celgene takes over Ariad at $40 post? Seemed to be a reasonable point of discussion..
micanwait, nice detective work..thanks..
This is not the time to be a hero:
http://stockcharts.com/h-sc/ui?s=$SPX&p=D&yr=0&mn=8&dy=2&id=p95138321694&a=265329638&listNum=59
SPX now at lower BB on the daily chart.....to be clear this alone is not a buy signal.
In addition, this leg down off 1415 to 1350 (65pts) equates to the first leg down from 1422 to 1357 (65 pts). While the market is oversold on several indicators, the market remains in a solid downtrend at this time. Respect the trend with the bears firmly in control for now.
Dam, even I can see that.. it bounced right off the 50DMA!
I hate to say this (gulp).. but, is the next leg up in the market (not Ariad, that's on auto pilot), nothing but a dead cat bounce?
Top small cap Biotech pick.
http://www.twst.com/yagoo/birhce3.html
IIIverson, you always win with the Arnold.. loved it!
Did I pick the right stock with Ariad? If what Harvey said is true, could we have a repeat? Dreamer?
http://finance.yahoo.com/q/bc?s=REGN&t=5y&l=on&z=l&q=l&c=
Yeah, Harvey mentioning that Ariad will mature to the likes of Celgene probably has a few from Ariad staying awake tonight... Wow, a 31 Billion market cap..
Let me put it this way.. Where do you think the technicals were when I bought most all my Ariad from $2.70 to $4.40? 'Nuff said.. I'm really not too concerned what your friends at Goldman or B of A do, to be honest with you..
I'll take the high potential of two new approved biotech compounds any day over a bunch of lines and graphs..